We are global key opinion leaders in laser eye surgery and keratoconus treatment. Members of our team have been elected to the global “PowerList100” of ophthalmology a record-breaking 8 times. This concentration of PowerList mentions is unique for an institute of our size on a national and international level
Dr. Paridaens performs the first transconjunctival orbital decompression for exophthalmus. Since then, Dr. Paridaens carried out more than 1,000 of these interventions.
Prof. Hafezi was part of the team that built the first CXL device, the UV-X 1000.
Seiler, Mrochen, Iseli and Hafezi found the Cross-Linking Congress, which is the most important international platform for CXL research to date.
Prof. Hafezi is the first author of the groundbreaking study, which reported the first successful treatment of ectasia after LASIK.
Prof. Hafezi is the first author of the study, which is the first to treat thin corneas with CXL.
Prof. Hafezi becomes Chairman of the University Eye Clinic in Geneva
Dr. Baydoun performs her first DMEK surgery. As the head of the NIIOS academy, she has since trained most of Europe’s DMEK surgeons.
Prof. Hafezi and Prof. Randleman introduce the term “PACK-CXL”: Cross-linking for corneal infections
Since 2014, ELZA members (Farhad Hafezi, Kaweh Mansouri, Nikki Hafezi) have been represented a total of seven times in the global “PowerList” of the most influential personalities in ophthalmology worldwide.
Theo Seiler and Farhad Hafezi successfully arrest Terrien’s disease for the first time in ophthalmology.
Farhad Hafezi named “World Keratoconus Expert” on Expertscape.
Kaweh Mansouri becomes a professor at the University of Denver in Colorado.
Farhad Hafezi is one of 6 living Swiss who have been awarded the title “Fellow of ARVO”. The FARVO title is a special award for everyone who has made outstanding contributions to the development of ophthalmology.
Members of ELZA have carried out the world’s first CXL at the slit lamp, which greatly simplifies the application.
ELZA members have led an international study that shows that a single PACK-CXL treatment for corneal infections is just as effective as drug administration for days and weeks.
ELZA develops the “sub400” protocol to treat ultrathin keratoconus corneas with CXL, published in the “American Journal of Ophthalmology”
ELZA members are the first in the world to successfully perform CXL on keratoglobus corneas.